Partner Selection
How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?
Pharma's Almanac
PAO-08-26-RT-01Aug 28, 2026
CMC and Investment
Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment
David Alvaro, Ph.D.; Daniel Smith, Ph.D.
Pharma's Almanac
PAO-01-26-NI-15Jan 15, 2026
Supply Chain
Future-Proofing a Volatile Supply Chain Through Modular Biomanufacturing
Rasmus Pedersen, Ph.D.; John Stewart; Peter Skals
Fujifilm Biotechnologies
PAO-06-25-CL-03Jul 7, 2025
Nitrosamine
IFF Pharma Solutions Launches Low Nitrite METHOCEL™ HPMC for Nitrosamine Mitigation
IFF
PR-04-25-NI-01Apr 8, 2025
HTS
The High-Throughput Screening Transformation in Modern Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-12Mar 2, 2025
Developability
Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments
Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.
Coriolis Pharma
PAO-01-25-CL-12Jan 27, 2025
Developability
Streamlining the Path to Approval with Developability and Pre-Formulation Platforms
Andrea Hawe
Coriolis Pharma
PAO-07-24-CL-11Aug 1, 2024
CRDO
Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development
Silvia Steyrer-Gruber
Coriolis Pharma
PAO-07-24-CL-05Jul 16, 2024
mRNA Manufacturing
Navigating mRNA Manufacturing with Flexibility and Innovation
Michael van der Horst, Ph.D.
Wacker Chemie AG
PAO-04-24-CL-02Apr 8, 2024
CDMO
Advanced Technologies Unlocking the Future of Drug Manufacturing
Jon Brice
Asymchem
PAO-03-24-CL-04Jan 29, 2024
Cleanrooms
Design–Build Cleanroom Projects: A Proven Risk Mitigating Methodology
Matt Dean; Mitchell Gonzales
AES Clean Technology Inc.
PAO-10-23-CL-06Nov 6, 2023
New CDMO Facility
Leveraging a State-of-the-Art CDMO Facility to Advance Healthcare
Grifols
PAO-02-23-PATV-04Feb 23, 2023
Overcoming the Challenges of an Ever-changing Biopharma Landscape
Integrity
PAO-01-23-PATV-01Jan 24, 2023
Quality by Design
A Concerted QbD Approach to Development and Manufacturing of Nucleic Acid Therapies
Grant Henderson, Ph.D.; Lynda Menard, Ph.D.
Vernal Biosciences
PAO-11-022-CL-06Jan 9, 2023
Viral Vectors
Risk-Based Optimization of Viral Vector Processes Adds Real Value
Elie Hanania, Ph.D.; Tatiana Mello, M.S.
Avid Bioservices
PAO-09-022-CL-05Oct 25, 2022
Pharma 4.0
Applying an Advanced Pharma 4.0 Perspective to Design the Facility of the Future
Steve Attig; Yuk Chun Chiu, M.S.E.; Yvonne Duckworth; Patricia Robbins; Dawn Wofford
CRB USA
PAO-06-022-CL-11Sep 8, 2022
CAPA Management
CAPA Management is Worth Doing, and Worth Doing Well
Helen Lowe
PAO-04-022-CL-11May 4, 2022
Regulatory
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review
U.S. Food & Drug Administration
PR-M03-22-03Mar 7, 2022
Nitrosamine
Supporting Drug Manufacturers with Emprove® Nitrosamine Declarations
Ulrich Reichert, M.D.R.A.
MilliporeSigma
PAO-02021-CL-05Feb 10, 2021
Roundtable
Q: Although there is no such thing as a truly “crisis-proof” organization, how are you working to mitigate risks for future crises like the COVID-19 pandemic?
Pharma's Almanac
PAP-Q4-20-NI-007Dec 9, 2020